YOLT-201
Phase 2Small molecule
YOLT-201 is one of 28 small molecule programs targeting Cardiomyopathy. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Cardiomyopathy
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskApproved
Bayer Aspirin
BayerApproved
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cordarone
WWyeth-Lederle Vaccines
Approved
Zocor
OOrganon and Co
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Imuran
LLegacy Health System
Approved
Rayos
RRoxane Laboratories
Approved
Ranexa
MMenarini International Operations Luxembourg SA
Approved
Inpefa
LLexicon Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cardiomyopathy2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YOLT-201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- YYolTech Therapeutics Co., Ltd